ATE443714T1 - Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen - Google Patents

Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Info

Publication number
ATE443714T1
ATE443714T1 AT02014617T AT02014617T ATE443714T1 AT E443714 T1 ATE443714 T1 AT E443714T1 AT 02014617 T AT02014617 T AT 02014617T AT 02014617 T AT02014617 T AT 02014617T AT E443714 T1 ATE443714 T1 AT E443714T1
Authority
AT
Austria
Prior art keywords
long
viral infections
peptide inhibitors
body cells
virus fusion
Prior art date
Application number
AT02014617T
Other languages
English (en)
Inventor
Dominique Bridon
Robert Dufresne
Nissab Boudjellab
Martin Robitaille
Peter Milner
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26832297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE443714(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE443714T1 publication Critical patent/ATE443714T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AT02014617T 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen ATE443714T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10

Publications (1)

Publication Number Publication Date
ATE443714T1 true ATE443714T1 (de) 2009-10-15

Family

ID=26832297

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02014617T ATE443714T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
AT00932570T ATE226593T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00932570T ATE226593T1 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Country Status (14)

Country Link
US (4) US7582301B1 (de)
EP (3) EP1179012B2 (de)
JP (3) JP4216480B2 (de)
CN (1) CN1351611A (de)
AT (2) ATE443714T1 (de)
AU (1) AU761591B2 (de)
BR (1) BR0010757A (de)
CA (1) CA2372338A1 (de)
DE (2) DE60043021D1 (de)
DK (1) DK1264840T3 (de)
ES (2) ES2334106T3 (de)
HK (1) HK1053128A1 (de)
PT (1) PT1264840E (de)
WO (1) WO2000069902A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE252601T1 (de) 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
ATE443714T1 (de) * 1999-05-17 2009-10-15 Conjuchem Biotechnologies Inc Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
CN1255548C (zh) 2001-06-15 2006-05-10 霍夫曼-拉罗奇有限公司 gp41片段的乙酰化
JP5385497B2 (ja) * 2002-09-24 2014-01-08 フロンティア バイオテクノロジーズ カンパニー リミテッド Ｈｉｖ感染のペプチド誘導体融合阻害剤
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
EP2418281B1 (de) 2003-10-24 2016-06-01 Gencia Corporation Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
US20080039532A1 (en) * 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
WO2007097903A2 (en) 2006-02-02 2007-08-30 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
CN100366633C (zh) * 2006-04-18 2008-02-06 河北师范大学 棕点湍蛙抗病毒多肽及其在制药中的应用
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
BRPI0715794A2 (pt) 2006-08-17 2013-07-23 Hoffmann La Roche conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
BRPI0811864A2 (pt) * 2007-05-16 2014-11-18 Conjuchem Biotechnologies Inc Derivados de ácido cistéico de peptídeos antivirais
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EP2604623A3 (de) 2007-08-08 2013-10-02 Novozymes Biopharma DK A/S Transferrinvarianten und Konjugate
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
KR101425404B1 (ko) * 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
EP2616487B1 (de) 2010-09-14 2015-03-25 F.Hoffmann-La Roche Ag Serpin-finger-fusionspolypeptid
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2834264A1 (de) 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptidkonjugate mit sphingolipid und aus hiv gp41 gewonnenen peptiden
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
EP3318124A3 (de) 2013-02-16 2018-05-30 Albumedix A/S Pharmakokinetisches tiermodell
EP2981334A4 (de) * 2013-04-03 2016-11-23 Univ California Zusammensetzungen und verfahren zur hemmung der viralen aktivität
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
CN103864921B (zh) * 2014-01-16 2017-12-26 苏州大学 双重靶向治疗癌症的叶酸‑阿霉素免疫制剂及其制备方法
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
CA3004790A1 (en) 2015-11-10 2017-05-18 Visterra, Inc. Lipopolysaccharide binding antibody-antimicrobial peptide conjugates and uses thereof
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
AU2018209940A1 (en) 2017-01-18 2019-07-11 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
EP4126064A1 (de) 2020-04-03 2023-02-08 Visterra, Inc. Antikörpermolekül-wirkstoff-konjugate und verwendungen davon
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
DK0578728T3 (da) 1991-04-05 1999-04-12 Genentech Inc Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5614487A (en) * 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
WO1996035451A1 (fr) 1995-05-10 1996-11-14 Kyowa Hakko Kogyo Co., Ltd. Nouveau complexe de toxines
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4086936B2 (ja) 1996-10-03 2008-05-14 株式会社ブリヂストン ダミーウェハ
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
JP2001522817A (ja) * 1997-11-07 2001-11-20 コンジュケム，インコーポレーテッド オピオイドと内因性担体の新規コンジュゲート
ATE406577T1 (de) * 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
EP1121425B1 (de) * 1998-10-13 2005-06-29 The University Of Georgia Research Foundation, Inc. Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
ATE443714T1 (de) * 1999-05-17 2009-10-15 Conjuchem Biotechnologies Inc Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
US20080039532A1 (en) * 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target

Also Published As

Publication number Publication date
EP2110381A1 (de) 2009-10-21
US20050070475A1 (en) 2005-03-31
US7608271B2 (en) 2009-10-27
WO2000069902A1 (en) 2000-11-23
EP1179012B2 (de) 2009-07-15
ES2185595T3 (es) 2003-05-01
ATE226593T1 (de) 2002-11-15
BR0010757A (pt) 2002-02-19
CA2372338A1 (en) 2000-11-23
JP2002544287A (ja) 2002-12-24
AU761591B2 (en) 2003-06-05
EP1179012B1 (de) 2002-10-23
US7582301B1 (en) 2009-09-01
US20080199483A1 (en) 2008-08-21
ES2185595T5 (es) 2009-12-17
HK1053128A1 (en) 2003-10-10
DE60000665T3 (de) 2009-10-29
DK1264840T3 (da) 2009-11-16
PT1264840E (pt) 2010-01-04
JP2009167208A (ja) 2009-07-30
EP1264840B1 (de) 2009-09-23
CN1351611A (zh) 2002-05-29
US20080176794A1 (en) 2008-07-24
JP4216480B2 (ja) 2009-01-28
EP1179012A1 (de) 2002-02-13
JP2008101021A (ja) 2008-05-01
EP1179012B9 (de) 2003-09-10
DE60000665T2 (de) 2003-06-26
AU5027100A (en) 2000-12-05
DE60000665D1 (de) 2002-11-28
EP1264840A1 (de) 2002-12-11
ES2334106T3 (es) 2010-03-05
DE60043021D1 (de) 2009-11-05

Similar Documents

Publication Publication Date Title
ATE443714T1 (de) Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
NO995263L (no) Konjugater av polyetylenglykol og interferon-<alfa> for terapi av infeksjoner
BR9812547A (pt) Proteìnas de fusão compreendendo proteìnas hiv-1 tat e/ou nef
CU23048A3 (es) Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
FI933740A (fi) PEG-interferonkonjugat
LU92175I2 (fr) Lixisénatide
DE60037450D1 (de) Funf-helix protein
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
NO20014857L (no) Makrocykliske peptider aktive mot Hepatitt C virus
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE425188T1 (de) Physiologisch wirksames polypeptidkonjugat mit verlängerter in vivo halbwertszeit
ATE516820T1 (de) Pegyliertes interleukin 10
TR200001961T2 (tr) Ifnar 2/IFN kompleksi.
DE69011122T2 (de) Rubella-e1 und c peptide.
NO983054L (no) Virale rekombinante pseudopartikler og anvendelse som vaksiner og som anti-tumormiddel
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
DE69513632T2 (de) Mikrogranulate enthaltend 5-nitroimidazolderivate
ATE347899T1 (de) Interferon nachahmende peptide und rekombinante proteine
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1264840

Country of ref document: EP